Metformin, a first-line therapy for type 2 diabetes, is associated with a reduced risk of heart failure in diabetic patients (82) and its cardioprotective effects, largely attributed to AMPK activation (81), have been validated in numerous animal and cell-based models (83–87). The gene discussed is PRKAA2; the disease is type 2 diabetes mellitus.